These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3768243)

  • 1. Partial metabolic clearances as determinants of the oral bioavailability of propranolol.
    Walle T; Walle UK; Olanoff LS; Conradi EC
    Br J Clin Pharmacol; 1986 Sep; 22(3):317-23. PubMed ID: 3768243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathway-selective sex differences in the metabolic clearance of propranolol in human subjects.
    Walle T; Walle UK; Cowart TD; Conradi EC
    Clin Pharmacol Ther; 1989 Sep; 46(3):257-63. PubMed ID: 2776391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective induction of propranolol metabolism by smoking: additional effects on renal clearance of metabolites.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    J Pharmacol Exp Ther; 1987 Jun; 241(3):928-33. PubMed ID: 3598909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stereoselective ring oxidation of propranolol in man.
    Walle T; Walle UK; Wilson MJ; Fagan TC; Gaffney TE
    Br J Clin Pharmacol; 1984 Nov; 18(5):741-8. PubMed ID: 6508983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Racial differences in propranolol enantiomer kinetics following simultaneous i.v. and oral administration.
    Sowinski KM; Lima JJ; Burlew BS; Massie JD; Johnson JA
    Br J Clin Pharmacol; 1996 Sep; 42(3):339-46. PubMed ID: 8877025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative account of propranolol metabolism in urine of normal man.
    Walle T; Walle UK; Olanoff LS
    Drug Metab Dispos; 1985; 13(2):204-9. PubMed ID: 2859169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stereochemical composition of propranolol metabolites in the dog using stable isotope-labeled pseudoracemates.
    Walle T; Wilson MJ; Walle UK; Bai SA
    Drug Metab Dispos; 1983; 11(6):544-9. PubMed ID: 6140137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stereoselective increase in propranolol bioavailability during chronic dosing in the dog.
    Bai SA; Wilson MJ; Walle UK; Walle T
    J Pharmacol Exp Ther; 1983 Nov; 227(2):360-4. PubMed ID: 6631718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
    Takahashi H; Ogata H; Warabioka R; Kashiwada K; Ohira M; Someya K
    J Pharm Sci; 1990 Mar; 79(3):212-5. PubMed ID: 2338628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presystemic and systemic glucuronidation of propranolol.
    Walle T; Fagan TC; Conradi EC; Walle UK; Gaffney TE
    Clin Pharmacol Ther; 1979 Aug; 26(2):167-72. PubMed ID: 455886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulatory as well as inhibitory effects of ethinyloestradiol on the metabolic clearances of propranolol in young women.
    Walle T; Fagan TC; Walle UK; Topmiller MJ
    Br J Clin Pharmacol; 1996 Apr; 41(4):305-9. PubMed ID: 8730976
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and metabolism of oral doses of a 4'-methylthio derivative of propranolol in man.
    Walle T; Walle UK; Cowart TD; Conradi EC; Gaffney TE
    Xenobiotica; 1990 Mar; 20(3):321-31. PubMed ID: 2336841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Propranolol metabolism in normal subjects: association with sex steroid hormones.
    Walle T; Walle K; Mathur RS; Palesch YY; Conradi EC
    Clin Pharmacol Ther; 1994 Aug; 56(2):127-32. PubMed ID: 8062488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans.
    Midha KK; Roscoe RM; Wilson TW; Cooper JK; Loo JC; Ho-Ngoc A; McGilveray IJ
    Biopharm Drug Dispos; 1983; 4(4):331-8. PubMed ID: 6661512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interactions of phenobarbital with propranolol in the dog. 2. Bioavailability, metabolism and pharmacokinetics.
    Vu VT; Bai SA; Abramson FP
    J Pharmacol Exp Ther; 1983 Jan; 224(1):55-61. PubMed ID: 6848749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of ageing on the hepatic clearance of propranolol.
    Castleden CM; George CF
    Br J Clin Pharmacol; 1979 Jan; 7(1):49-54. PubMed ID: 760742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Food effects on propranolol systemic and oral clearance: support for a blood flow hypothesis.
    Olanoff LS; Walle T; Cowart TD; Walle UK; Oexmann MJ; Conradi EC
    Clin Pharmacol Ther; 1986 Oct; 40(4):408-14. PubMed ID: 3757404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct measurement of propranolol bioavailability during accumulation to steady-state.
    Wood AJ; Carr K; Vestal RE; Belcher S; Wilkinson GR; Shand DG
    Br J Clin Pharmacol; 1978 Oct; 6(4):345-50. PubMed ID: 698031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between oral propranolol and hydralazine.
    McLean AJ; Skews H; Bobik A; Dudley FJ
    Clin Pharmacol Ther; 1980 Jun; 27(6):726-32. PubMed ID: 7379440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No stereoselective first-pass hepatic extraction of propranolol.
    Jackman GP; McLean AJ; Jennings GL; Bobik A
    Clin Pharmacol Ther; 1981 Sep; 30(3):291-6. PubMed ID: 7273593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.